Discovery and Innovation

Aeglea

[ey-glee-uh]

From the Latin name Aegle.
The goddess of radiant good
health. Daughter of Asclepius,
the god of medicine.

As a leader in creating and developing next generation human enzymes to provide solutions for disease with unmet medical need, we are focused on providing safe and effective products to patients.

What does success mean to us? It means…

  • Unlocking the potential therapeutic value of engineered human enzymes while avoiding immune responses
  • Meeting serious unmet medical needs in rare genetic diseases, inborn errors of metabolism, and cancers with ground-breaking treatments
  • Transforming lives, especially those of children and families

Built on discovery, technology, and opportunity, our biotechnology company was founded in 2013 to develop and bring to market next generation human enzymes.

Read on to meet our management and scientific team – these are the inspiring individuals at the forefront of developing next generation human enzymes.

Leadership Team

Anthony Quinn, M.B Ch.B, Ph.D.

President & Chief Executive Officer

Charles N. York II, M.B.A.

Chief Financial Officer

Leslie Sloan, Ph.D.

Leslie Sloan, Ph.D.

Chief Operating Officer

Ravi M. Rao, MB. BChir, Ph.D.

Chief Medical Officer

Michael C. Hanley, M.B.A.

Michael C. Hanley, M.B.A.

Chief Commercial Officer

Scott W. Rowlinson, Ph.D.

Vice President of Research

Board of Directors

Suzanne L. Bruhn, Ph.D.

Suzanne L. Bruhn, Ph.D.

Independent Director

Russell J. Cox

Chief Executive Officer, Vital Therapies

V. Bryan Lawlis, Ph.D.

V. Bryan Lawlis, Ph.D.

Independent Director

Ivana Magovčević-Liebisch, Ph.D., J.D.

Executive Vice President, Chief Business Officer, Ipsen

Sandy Mahatme

Executive Vice President, Chief Financial Officer, and Chief Business Officer, Sarepta Therapeutics, Inc.

Anthony Quinn, M.B Ch.B, Ph.D.

President & Chief Executive Officer

Armen Shanafelt, Ph.D.

General Partner, Lilly Ventures

Contact Us

Aeglea BioTherapeutics

CORPORATE HEADQUARTERS
901 S. MoPac Expressway, Barton Oaks Plaza One,
Suite 250, Austin, TX 78746

MAILING ADDRESS
901 S. MoPac Expressway, Barton Oaks Plaza One,
Suite 250, Austin, TX 78746

TELEPHONE NUMBER
(512) 942-2935

FAX NUMBER
(512) 872-5121

INVESTOR INQURIES
investors@aegleabio.com

MEDIA INQUIRIES
media@aegleabio.com

Send Us a Message
  • This field is for validation purposes and should be left unchanged.

Ivana Magovčević-Liebisch, Ph.D., J.D.

Executive Vice President, Chief Business Officer, Ipsen

Dr. Magovčević-Liebisch has 20 years of senior management experience in biopharma with expertise in corporate development, M&A, IP and legal strategy, and pipeline and product portfolio development. She is currently the executive vice president, chief business officer of Ipsen, a biopharmaceutical group focused on innovation and specialty care with medicines in oncology, neuroscience and rare diseases. Dr. Magovčević-Liebisch previously served as the executive vice president, chief strategy and corporate development officer of Axcella Health Inc. From 2013 to 2017, she was senior vice president and head of global business development at Teva Pharmaceutical Industries, where she spearheaded multiple transactions ranging from licensing to acquisitions for the specialty drug business. From 2001 to 2013, Dr. Magovčević-Liebisch worked for Dyax Corp, rising to the positions of executive vice president and chief operating officer. During that time, she established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor®, for treatment of hereditary angioedema attacks. From 1998 to 2001, she was patent counsel and director of intellectual property at Transkaryotic Therapies. Dr. Magovčević-Liebisch has a B.A. in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University Medical School and a J.D. in High Technology law from Suffolk University Law School.

Charles N. York II, M.B.A.

Chief Financial Officer

Aeglea Biotherapeutics, Inc.

Mr. York has raised over $250 million in public and private financings for Aeglea, including the Company’s initial public offering in 2016. His current responsibilities include Aeglea’s finance, accounting, facilities, human resources, and investor and public relations functions. Prior to joining Aeglea, Mr. York held finance leadership positions in public companies and high-growth start-ups in the life sciences and technology industries. Mr. York’s corporate finance transactional background includes an IPO, a private equity buyout, a corporate spin-off, and an acquisition. Mr. York is a Certified Public Accountant (CPA) who earned his B.S. in accounting from the University of Connecticut and his M.B.A. from the McCombs School of Business at the University of Texas at Austin, where he is now a member of the Healthcare Innovation Board.

Scott W. Rowlinson, Ph.D.

Vice President of Research

Dr. Rowlinson joins Aeglea from Eli Lilly and Company. He has a proven track record of scientific productivity in biologics drug discovery and development, and has demonstrated leadership in coordinating drug discovery to clinical development. These efforts led to three successful IND submissions, the most advanced being in Phase 2 development. Dr. Rowlinson has a wealth of experience in the broader concepts of biomolecule drug development, including uncovering factors involved in clinical portfolio attrition and optimal integration of companion diagnostic development and drug development. He holds a Ph.D. in physiology and biochemistry from University of Queensland in Brisbane, Australia.

Joseph E. Tyler, M.S.

Vice President of Manufacturing

Mr. Tyler has worked for over 40 years in the pharmaceutical and biotechnology field in process development, manufacturing, and CMC program management. Mr. Tyler has worked for Schering Corp, Lederle Laboratories, Abbott Laboratories, Stryker Biotech, GelTex Pharmaceuticals, Salix Pharmaceuticals, Momenta Pharmaceuticals, KBI Biopharma, and Proteon Therapeutics. He has managed CMC development programs, ultimately gaining approval in the U.S. and Europe for five new medications, including sevelamer, cosevelem, rifaximin, a new antibiotic indicated for C. difficile infections and a novel lipid management drug. Mr. Tyler recently was the CMC program leader for a recombinant human enzyme that will be starting Phase 3 clinical trials this year. He received a B.S. in chemical engineering from Carnegie Mellon University and an M.S. in biochemical engineering from Cornell University.

Stephen Eckert, Ph.D.

Vice President of Biometrics

Prior to joining Aeglea, Dr. Eckert served as Vice President, Global Clinical Affairs for Acelity. He has over 20 years of experience in biostatistical design and analysis for pharmaceutical, biologic, and medical device clinical trials, including several successful regulatory submissions across multiple therapeutic areas. In addition to experience with medical device studies for wound healing with Acelity, he has experience with endocrine system clinical studies with Eli Lilly & Company; cardiovascular, metabolic, and solid tumor clinical studies with Pfizer; leukemia clinical studies with Genzyme; and studies of inborn errors of metabolism with Synageva Biopharma. He has also held team leader roles providing strategic product development direction for teams comprised of physicians, regulatory scientists, and other drug development experts. Dr. Eckert holds a B.S. in Applied Mathematics, as well as M.S. and Ph.D. degrees in Statistics, from Texas A&M University.

Russell J. Cox

Chief Executive Officer, Vital Therapies

Mr. Cox is chief executive officer and a member of the board of directors at Vital Therapies.  Previously he served as executive vice president and chief operating officer of Jazz Pharmaceuticals.  As COO he held responsibility for the company’s Commercial, R&D, Manufacturing, International, and Global Molecule Leadership teams. He worked in a variety of escalating senior management roles from 2010 to 2018, including executive vice president and chief commercial officer from March 2012 to May 2014. From January 2009 to January 2010, he was senior vice president and chief commercial officer of Ipsen Group, and from 2007 until December 2008 he was vice president of marketing at Tercica, Inc., a biotechnology company acquired by Ipsen Group. From 2003 to 2007, he was with Scios, Inc. (acquired by Johnson & Johnson in 2003), where he served as vice president of marketing. Prior to 2003, Mr. Cox was with Genentech, Inc. for 12 years, where he was a product team leader responsible for the company’s growth hormone franchise and led numerous product launches as a group product manager. Mr. Cox received a B.S. in biomedical science from Texas A&M University.

Sandy Mahatme

Executive Vice President, Chief Financial Officer, and Chief Business Officer, Sarepta Therapeutics, Inc.

Mr. Mahatme is executive vice president and chief financial officer of Sarepta Therapeutics where he leads Sarepta’s finance, business development, technical operations, facilities, IT and investor and public relations functions. From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including senior vice president of corporate development, senior vice president of finance, corporate treasurer, and head of tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the corporate development department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing, and global manufacturing expansion. Prior to working at Celgene, Mr. Mahatme worked for Pfizer Inc. for eight and a half years in senior roles in business development and corporate tax. Mr. Mahatme started his career at Ernst & Young LLP, where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Law degrees from Cornell Law School and New York University School of Law and is a member of the New York State Bar Association. In addition to Aeglea, Mr. Mahatme is also a board member of Flexion Therapeutics, Inc. and Elcelyx Therapeutics, Inc., both biopharmaceutical companies.

Anthony Quinn, M.B Ch.B, Ph.D.

President & Chief Executive Officer

Dr. Quinn is the President & Chief Executive Officer at Aeglea BioTherapeutics and most recently served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma until the company’s acquisition by Alexion Pharmaceuticals in 2015. During his tenure at Synageva, he played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency and in building the company’s research and development organization and rare disease drug pipeline. Prior to his role at Synageva, Dr. Quinn served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. Previously, he was a professor of dermatology at Barts and The London School of Medicine. He received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and a Ph.D. from the University of Newcastle upon Tyne. Dr. Quinn completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London. Dr. Quinn currently serves as a member of the board of directors for Kaleido Biosciences, Inc. and Generation Bio.

Armen Shanafelt, Ph.D.

General Partner, Lilly Ventures

Dr. Shanafelt is a general partner at Lilly Ventures. Prior to joining Lilly Ventures in 2009, he had over 24 years of experience in the pharmaceutical, biotechnology, and diagnostic industries. In addition to Aeglea, Dr. Shanafelt serves as a director on the boards of Aileron Therapeutics (ALRN), Protagonist Therapeutics (PTGX), Sutro Biopharma, Surface Oncology and Symic Bio, where he serves as chairman. He is a Kauffman Fellow (class of 2014). Dr. Shanafelt received his B.S. in chemistry and physics from Pacific Lutheran University and his Ph.D. in chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute.

Suzanne L. Bruhn, Ph.D.

Suzanne L. Bruhn, Ph.D.

Independent Director

Dr. Bruhn most recently served as president and chief executive officer of Proclara Biosciences, a privately held, clinical-stage company pioneering a novel approach to treat disorders of protein misfolding including Alzheimer’s and Parkinson’s Disease, as well as orphan amyloidoses. Prior to that she served as president and CEO of Promedior, Inc., a privately held, clinical-stage immunotherapy company developing targeted therapeutics to treat diseases involving fibrosis. She successfully negotiated an exclusive agreement for the right to acquire the company by Bristol-Myers Squibb in 2015. Prior to that, Dr. Bruhn held a series of positions with increasing responsibility at Shire Human Genetic Therapies (HGT), a division of Shire plc, specializing in the development and commercialization of treatments for orphan diseases. During her tenure at Shire HGT, Dr. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management and for global regulatory affairs. She played a key role in the development, registration and global expansion of Shire’s orphan product portfolio. Prior to her time at Shire, Dr. Bruhn held various positions at Cytotherapeutics, Inc., a biotechnology company. Dr. Bruhn holds a Ph.D. in chemistry from Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School. In addition to Aeglea, Dr. Bruhn currently serves as a director on the boards of Novelion Therapeutics (NASDAQ: NVLN), and Pliant Therapeutics, a privately held biotechnology company. She was formerly on the board of directors of Raptor Pharmaceuticals (NASDAQ: RPTP), until its acquisition by Horizon Pharma plc (NASDAQ:HZNP).

Aaron Schuchart, M.B.A.

Aaron Schuchart, M.B.A.

Chief Business Officer

Prior to joining Aeglea, Mr. Schuchart served as senior vice president of business development and strategic alliances at Coherus Biosciences, where he played a role in growing the company from early platform stage to a fully integrated, late-stage clinical company. Prior to Coherus, Mr. Schuchart was head of business development and strategic planning at Novartis’ diagnostics division until its acquisition by Grifols. He also advised on and led portfolio planning projects, financings, and strategic transactions for numerous biotech clients as managing director of Proaltus Partners, LLC. Earlier in his career, he served in various business and operational leadership roles at Mendel Biotechnology and Amgen. Mr. Schuchart holds a B.S. in accounting from Texas Tech University, an M.B.A. from the UCLA Anderson School of Management, and is a Certified Licensing Professional (CLP).

Leslie Sloan, Ph.D.

Leslie Sloan, Ph.D.

Chief Operating Officer

Prior to joining Aeglea, Dr. Sloan served as vice president of global R&D project management and analytics, as well as president and R&D site head at Ipsen Bioscience Previously, she held several global roles at Pfizer and Eli Lilly. Dr. Sloan has been instrumental to 15 successful new or supplemental market authorization submissions in Europe and the United States. She was a member of the Ipsen R&D leadership team, the Pfizer R&D clinical candidate survival council and candidate quality guidelines committee and co-chair of the Bioorganic Chemistry Gordon Research Conference. Dr. Sloan earned a B.S. in chemistry and medical biology from Southeastern Oklahoma State University and a Ph.D. in bioorganic chemistry from Yale University under the direction of Dr. Alanna Schepartz.

Ravi M. Rao, MB. BChir, Ph.D.

Chief Medical Officer

Prior to joining our Company, Dr. Rao served in leadership roles at GlaxoSmithKline plc, including as Vice President, Global Medical Affairs Head, Immunology and Specialty Medicine from September 2016 to October 2019; and as Vice President, Head Unit Physician and Medicines Development Leader, Immuno-inflammation Therapy Area Unit from April 2012 to August 2016. Prior to that, from 2007 to 2012, Dr. Rao served in various roles of increasing responsibility at Roche Genentech, including as Group Medical Director, Product Development Immunology and Clinical Development Site Head. Before joining industry, Dr. Rao was a Senior Lecturer and Consultant Rheumatologist at Imperial College, London. He holds a B.A. in Medical Sciences and an MB. BChir from the University of Cambridge, an MRCP from the Royal College of Physicians, and a Ph.D. from Imperial College School of Medicine, University of London. Dr. Rao also completed a post-doctoral research fellowship at Harvard Medical School.

Michael C. Hanley, M.B.A.

Michael C. Hanley, M.B.A.

Chief Commercial Officer

Mr. Hanley has nearly 25 years of experience in the biopharmaceutical and healthcare industries. Prior to joining Aeglea, Mr. Hanley served as Vice President and U.S. Chief Commercial Officer of Esteve Pharmaceuticals, S.A., where he played a key role in identifying a new corporate strategic vision and leading the establishment of a new U.S affiliate. Previously, Mr. Hanley served in various roles of increasing responsibility at Horizon Therapeutics PLC, a global biopharmaceutical company, where he had P&L responsibility for the company’s rare disease portfolio. Prior to Horizon, Mr. Hanley served in various commercial leadership roles at the U.S. affiliate of H. Lundbeck A/S, a global pharmaceutical company, where he led the launch and life cycle strategy of a product for a rare and devastating form of epilepsy. Mr. Hanley holds a B.B.A. in Marketing from the University of Notre Dame and an M.B.A. from the Kellogg School of Management at Northwestern University.

V. Bryan Lawlis, Ph.D.

V. Bryan Lawlis, Ph.D.

Independent Director

Dr. Lawlis has nearly 40 years of experience in the biotechnology industry, including extensive experience as a director and officer. Dr. Lawlis served as CEO of Itero BioPharmaceuticals, LLC from 2011 to 2017 and from 2007 to 2011 was co-founder and CEO of Itero BioPharmaceuticals, Inc. He was president and CEO of Aradigm Corporation from 2001 to 2006. From 1996 to 2001, Dr. Lawlis co-founded Covance Biotechnology Services and held the positions of president, CEO and executive chairman. Dr. Lawlis worked at Genentech from 1981 to 1996 and rose to the position of vice president of process science. Dr. Lawlis’s current board appointments include independent directorships at Biomarin Pharmaceutical, Geron Corporation, and Coherus Biosciences. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in biochemistry from Washington State University.